Welcome to our dedicated page for Humana news (Ticker: HUM), a resource for investors and traders seeking the latest updates and insights on Humana stock.
Humana Inc. reports news around its U.S. healthcare business, combining Humana insurance services with CenterWell healthcare services. Company updates commonly address Medicare Advantage and other health plan membership, Insurance segment benefit ratios, GAAP and adjusted earnings, full-year guidance, and capital returns through quarterly dividends.
News also covers CenterWell's senior-focused primary care, home health, pharmacy, hospice and retail pharmacy activities; prescription access and home delivery partnerships; healthcare research tied to medication adherence and chronic disease care; palliative care arrangements; health data interoperability; and board refreshment or other governance actions.
Humana (NYSE:HUM) announced Humana Community Day 2026, a nationwide day of service on Wednesday, Aug. 26, 2026, mobilizing thousands of employees to volunteer across U.S. communities. The company-wide initiative targets local health drivers such as food insecurity, neighborhood revitalization and social connection.
In 2026, enterprise-driven activities will focus on Louisville (KY), Central and South Florida, San Antonio (TX) and Baton Rouge (LA) through partnerships with local nonprofits, while employees elsewhere can join local or virtual projects. In 2025, more than 12,000 employees joined 220 events across 27 states and Puerto Rico, and the 2026 effort aims to build on this reach, reinforcing Humana’s broader 65-year commitment to community health and health equity through the Humana Foundation and CenterWell.
Humana (NYSE: HUM) announced the election of Paul Smith and Frederick Crawford to its Board of Directors, effective immediately, bringing the Board to 13 members. Smith is Chief Commercial Officer at Anthropic PBC and has over 30 years’ experience scaling global go-to-market strategies at major enterprise technology companies, including ServiceNow, Salesforce and Microsoft.
Crawford has more than three decades of financial and operational experience in insurance and banking, having served as CFO at CNO Financial Group and Lincoln Financial Group, and as President and COO of Aflac until his 2024 retirement. According to Humana, their combined expertise in AI-enabled technology adoption, capital allocation and risk management is expected to complement the Board as it pursues a long-term vision of becoming a consumer healthcare company.
Humana (NYSE:HUM) reported 2Q26 GAAP EPS of $5.73 and Adjusted EPS of $7.61, versus $4.51 and $6.27 in 2Q25. Year-to-date 2026 GAAP and Adjusted EPS were $15.55 and $17.91, slightly above YTD 2025’s $14.81 and $17.85.
Consolidated 2Q26 revenues rose to $40.9 billion from $32.4 billion. The Insurance segment reported a 2Q26 GAAP benefit ratio of 91.2%, in line with guidance, and the company affirmed FY26 Insurance benefit ratio guidance of 92.75% ±25 bps.
Humana affirmed FY26 Adjusted EPS guidance of at least $9.00 but reduced FY26 GAAP EPS guidance to at least $6.52 from at least $8.36, versus FY25 GAAP EPS of $9.84 and Adjusted EPS of $17.14. Management cited a year-over-year decline in FY26 Adjusted EPS due to Star Ratings headwinds for Bonus Year 2026, net of mitigation.
The consolidated GAAP operating cost ratio improved to 9.8% in 2Q26 from 11.0% in 2Q25, with Adjusted operating cost ratio at 9.7% versus 10.9%. Insurance segment income from operations was $820 million (GAAP) and $824 million (Adjusted), up from $766 million and $770 million in 2Q25.
Humana reaffirmed FY26 individual Medicare Advantage membership growth of approximately 25% over 2025 and reported year-to-date growth of 130,900 patients (27%) in CenterWell Senior Primary Care. The company also expanded its Medicaid presence with a statewide Illinois Medicaid managed care contract expected to go live in January 2027, where it was the only new entrant among six total awardees.
Humana (NYSE:HUM), through Humana Healthcare Research, reported a new Medicare Advantage study published in Health Affairs Scholar finding that favorable selection estimates are substantially below widely cited figures. According to Humana Healthcare Research, applying a single methodological refinement—using comprehensive encounter data on the full MA population—reduced favorable selection estimates by 42%-65% relative to the commonly cited 10%-15% range, including MedPAC estimates. The study estimated favorable selection of 4.9%-5.8% for 2020–2022, indicating a smaller impact on MA payments than prior analyses suggest and highlighting the importance of continued methodological refinement in MA payment policy.
Humana Foundation (NYSE:HUM) announced over $12.2 million in 2026 grants to advance emotional health, focusing on senior and veteran loneliness, depression and social isolation.
Funding supports 13 nonprofits and five university research teams across multiple states, scaling community programs and innovative research in emotional health and nutrition.
Humana (NYSE:HUM) will release its second quarter 2026 (2Q26) financial results and prepared management remarks at 6:00 a.m. ET on July 29, 2026. A live Q&A conference call and webcast will follow at 8:00 a.m. ET via the Investor Relations website.
Humana (NYSE:HUM) was selected by the Illinois Department of Healthcare and Family Services to serve members statewide in HealthChoice Illinois, the Medicaid managed care program.
The contract expands Humana’s role across 102 counties, builds on its dual-eligible experience, and includes partnerships in maternal health, behavioral health, and supportive housing. Humana’s HealthChoice plan is slated to go live in January 2027.
Humana (NYSE:HUM), CenterWell and the National Hispanic Medical Association announced the first 2026 Resident Physician Scholarship Program recipients. Seven bilingual (English/Spanish) internal and family medicine residents in Florida will each receive $10,000, structured mentorship, leadership training, and experiential learning in CenterWell senior primary care centers.
Humana (NYSE:HUM) signed a definitive agreement to divest all or substantially all of its minority interest in Gentiva, a leading end-of-life care provider. The stake is valued at approximately $900 million, with proceeds for general corporate purposes. Closing is expected in Q3 2026, and Humana does not anticipate a material impact to 2026 earnings.
Summary not available.